Skip to main content
Signal8

Cardiol Therapeutics Inc. (CRDL) Form 6-K — Nov 12, 2026

$CRDLForm 6-KFiled Nov 12, 2026, 4:21 PM ET0001104659-26-126269Original filing

Cardiol Therapeutics filed unaudited Q3 2026 financials showing a quarterly net loss of CAD 13.3 million, widened from CAD 10.0 million a year earlier, with nine-month losses of CAD 30.2 million versus CAD 26.6 million in 2025. The loss increase was driven largely by a CAD 3.9 million non-cash charge from the derivative warrant liability; operating losses were roughly flat quarter-over-quarter. The clinical-stage company has no revenue.

Key figures

Total Debt
5282533
Total Assets
32885787
Cash Position
29229802
Shares outstanding
121617823
Weighted avg shares q3
118028542
Warrant exercise proceeds cad
10047603
Unit financing gross proceeds cad
14850001

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    Cardiol Therapeutics Inc. (CRDL) Form 6-K — Nov 12, 2026: AI Analysis | Signal8